Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial
Chimeric Therapeutics (ASX:CHM) has reported one leukaemia patient has shown a complete response in its latest drug trial.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
IPL | Ann: Transactions Update | 22/08/24 | 0 | 97 | |||
|
|||||||
IPL | Ann: FY25 First Quarter Dividend | 20/08/24 | 0 | 69 | |||
|
|||||||
IPL | Ann: D&O Ongoing Disclosure | 10/07/24 | 0 | 88 | |||
|
|||||||
IPL | Ann: D&O Ongoing Disclosure | 04/07/24 | 0 | 79 | |||
|
|||||||
IPL | Ann: Results of Annual Shareholder Meeting 2024 | 26/06/24 | 0 | 77 | |||
|
|||||||
IPL | Ann: Annual Shareholder Meeting 2024 | 26/06/24 | 0 | 83 | |||
|
|||||||
IPL | Ann: FY24 Sustainability Report and Climate-Related Disclosures | 28/05/24 | 0 | 109 | |||
|
|||||||
IPL | Ann: Notice of Annual Shareholder Meeting | 24/05/24 | 0 | 99 | |||
|
See All Discussions